This is an open-label, phase II study of TGR-1202 in patients with relapsed or refractory (R/R) Grade 1, 2, or 3A follicular lymphoma (FL). FL is the most common subtype of indolent lymphoma. The…
ONCOLOGY
Dec 12, 2019
The Hematology and Oncology series, the 12th World Hematology and Oncology Congress, scheduled to be held on March 2- 3, 2020 at Edinburgh, Scotland. It will be organized around the theme “…
Dec 11, 2019
A Children’s Oncology Group Study AALL1331 suggests that Blinatumomab was superior over chemotherapy as post-reinduction consolidation prior to hematopoietic stem cell transplantation among…
Dec 11, 2019
A Children’s Oncology Group Study AALL1331 suggests that Blinatumomab was superior over chemotherapy as post-reinduction consolidation prior to hematopoietic stem cell transplantation among…
Dec 10, 2019
This is a case of a 62-year-old female who had a past medical history of FIGO stage IIB cervical cancer (squamous cell carcinoma pT2bN0M0). In 1987, she underwent radical hysterectomy with…
Dec 09, 2019
Dr. Perales discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. There is potential to move CAR T cells earlier in treatment of patients…
Dec 08, 2019
Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to a new study. Out of…
Dec 06, 2019
In this study, they have evaluated the efficacy and safety of FOLFIRI maintenance treatment after FOLFIRINOX induction in a retrospective single-center study. Patients with advanced PDA treated…